-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
-
Summary
-
ZyVersa Therapeutics, Inc. quarterly/annual Income Tax Expense (Benefit) history and growth rate from Q3 2022 to Q2 2024.
- ZyVersa Therapeutics, Inc. Income Tax Expense (Benefit) for the quarter ending June 30, 2024 was $9.71K.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Growth (%)